Current Edition


Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Leqvio arrives with high sales expectations, but uptake could be slow as insurers and doctors weigh the drug’s safety and cost-effectiveness. Novartis on Wednesday won Food …

Continue Reading →

Novartis finalizes deal to make new heart drug widely available in England

Novartis has made a big bet on Leqvio and now the U.K. government has, too, motivated by the prevalence of heart disease and its strong …

Continue Reading →

FDA clears Rocket to resume testing gene therapy for a rare heart disease

Rocket’s program has been in limbo since early May, when the company surprised investors and analysts with news of the trial’s stoppage. That announcement stalled …

Continue Reading →